This article is part of the supplement: AIDS Vaccine 2009
Oral presentation
S01-04 OA. Phenotypic analyses of CD8+ T cells that mediate virus inhibition from HIV-1 vaccinees and HIV-1+ virus controllers
1 DHVI and Surgery, Duke University Medical School, Durham, USA
2 ImmunoTechnology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
3 Immunology Core Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
4 Duke University Medical Center; DHVI and Surgery, Durham, NC, USA
5 University of Alabama, Department of Medicine, Birmingham, AL, USA
6 Duke University Medical Center, Department of Pediatrics, Durham, NC, USA
7 Duke University Medical Center; DHVI and Medicine, Durham, NC, USA
8 Duke University Medical Center; DHVI, Immunology and Surgery, Durham, NC, USA
9 Duke University Medical Center; Department of Surgery, Durham, NC, USA
10 Viral Pathogenesis Laboratory; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
11 Duke University Medical Center; DHVI, Immunology, and Medicine, Durham, NC, USA
12 Duke University Medical Center, DHVI, Surgery and Immunology, Durham, NC, USA
Retrovirology 2009, 6(Suppl 3):O1 doi:10.1186/1742-4690-6-S3-O1
Published: 22 October 2009First paragraph (this article has no abstract)
CD8-mediated virus inhibition can be detected in HIV-1+ subjects controlling virus replication in the absence of ART. Characterizing the CD8+ T cells that mediate virus inhibition is important for determining the nature of CD8+ T cells that need to be elicited by an HIV-1 vaccine.